|
| 36152970 | Expert opinion: Reconsidering How It Begins: Response to Gray Zone Article About Head and Neck Cancer in a Young Pregnant Woman. | Int J Radiat Oncol Biol Phys | 2023 |
| 37317810 | HPV16/18 Antibody Responses After a Single Dose of Nonavalent HPV Vaccine. | Pediatrics | 2023 |
| 36977289 | Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. | J Clin Oncol | 2023 |
| 37464928 | Intensified Adjuvant Treatment for High-Risk Resected Cutaneous Angiosarcoma of the Head and Neck. | Otolaryngol Head Neck Surg | 2023 |
| 37431689 | Feasibility of 5-fluorouracil and imiquimod for the topical treatment of cervical intraepithelial neoplasias (CIN) 2/3. | Int J Gynaecol Obstet | 2023 |
| 36521102 | Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline. | J Clin Oncol | 2023 |
| 36517408 | A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance. | Eur Urol Focus | 2023 |
| 36765627 | Integrating Immunotherapy into Multimodal Treatment of Head and Neck Cancer. | Cancers (Basel) | 2023 |
| 36658129 | Author Correction: Head and neck squamous cell carcinoma. | Nat Rev Dis Primers | 2023 |
| 34583290 | The impact of socioeconomic and geographic factors on access to transoral robotic/endoscopic surgery for early stage oropharyngeal malignancy. | Am J Otolaryngol | 2022 |
| 35740559 | Clinical Study of Aspirin and Zileuton on Biomarkers of Tobacco-Related Carcinogenesis in Current Smokers. | Cancers (Basel) | 2022 |
| 35761436 | Precision medicine: Sustained response to erdafitinib in FGFR2-mutant, multiply recurrent ameloblastoma. | Cancer Rep (Hoboken) | 2022 |
| 35428778 | Targeted CUL4A inhibition synergizes with cisplatin to yield long-term survival in models of head and neck squamous cell carcinoma through a DDB2-mediated mechanism. | Cell Death Dis | 2022 |
| 35625959 | Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer. | Cancers (Basel) | 2022 |
| 35565256 | Randomized Crossover Trial Evaluating Detoxification of Tobacco Carcinogens by Broccoli Seed and Sprout Extract in Current Smokers. | Cancers (Basel) | 2022 |
| 35681620 | A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer. | Cancers (Basel) | 2022 |
| 35940825 | Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. | J Immunother Cancer | 2022 |
| 35929989 | STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer. | Clin Cancer Res | 2022 |
| 36165722 | c-Met Signaling as a Therapeutic Target in Head and Neck Cancer. | Cancer J | 2022 |
| 36052496 | Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. | Cancer Res | 2022 |
| 36052495 | Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. | Cancer Res | 2022 |
| 35091445 | Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer. | Clin Cancer Res | 2022 |
| 33481911 | MEK/ERK signaling is a critical regulator of high-risk human papillomavirus oncogene expression revealing therapeutic targets for HPV-induced tumors. | PLoS Pathog | 2021 |
| 33614939 | Clinical trials optimizing investigator and self-collection of buccal cells for RNA yield. | Laryngoscope Investig Otolaryngol | 2021 |
| 34884999 | Immunotherapy Approaches in HPV-Associated Head and Neck Cancer. | Cancers (Basel) | 2021 |
| 34779417 | Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. | J Clin Invest | 2021 |
| 33991232 | Precision and Immunoprevention Strategies for Tobacco-Related Head and Neck Cancer Chemoprevention. | Curr Treat Options Oncol | 2021 |
| 34209641 | Targeting NEDDylation as a Novel Approach to Improve the Treatment of Head and Neck Cancer. | Cancers (Basel) | 2021 |
| 34207599 | NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. | Cancers (Basel) | 2021 |
| 34255745 | Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions. | JCI Insight | 2021 |
| 32545260 | Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. | Cancers (Basel) | 2020 |
| 32073648 | A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. | Cancer | 2020 |
| 33243986 | Head and neck squamous cell carcinoma. | Nat Rev Dis Primers | 2020 |
| 30642285 | Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome. | BMC Cancer | 2019 |
| 31661135 | Gene targets of sulforaphane in head and neck squamous cell carcinoma. | Mol Med Rep | 2019 |
| 31520512 | Neoadjuvant chemotherapy improves survival compared with concurrent chemoradiation alone in nasopharyngeal carcinoma patients with N3 disease. | Head Neck | 2019 |
| 31346466 | A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab. | Biomark Res | 2019 |
| 31308059 | Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. | Clin Cancer Res | 2019 |
| 31143513 | Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT. | Oncoimmunology | 2019 |
| 30683736 | Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer. | J Exp Med | 2019 |
| 30449525 | Current Concepts in Chemotherapy for Head and Neck Cancer. | Oral Maxillofac Surg Clin North Am | 2019 |
| 29061643 | Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. | Clin Cancer Res | 2018 |
| 29931076 | Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. | JAMA Oncol | 2018 |
| 30291796 | Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives. | Cancer | 2018 |
| 29440171 | Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. | Cancer Res | 2018 |
| 28029303 | E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. | J Clin Oncol | 2017 |
| 28408386 | Increased PD-1<sup>+</sup> and TIM-3<sup>+</sup> TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients. | Cancer Immunol Res | 2017 |
| 28352657 | Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. | JCI Insight | 2017 |
| 28559019 | IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer. | Oral Oncol | 2017 |
| 28821544 | When the Damage Is Done: Selecting Patients for Head and Neck Cancer Chemoprevention Trials. | Cancer Prev Res (Phila) | 2017 |